Julian R F Walters

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2260487/publications.pdf

Version: 2024-02-01

66343 60623 7,051 139 42 81 citations h-index g-index papers 142 142 142 8066 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Common Genetic Variants in the Bile Acid Synthesis Enzyme CYP7A1 Are Associated With Severe Primary Bile Acid Diarrhea. Gastroenterology, 2022, 163, 517-519.e2.	1.3	3
2	A practical approach to the patient with chronic diarrhoea. Clinical Medicine, 2021, 21, 124-126.	1.9	5
3	Differential effects of bile acids on the postprandial secretion of gut hormones: a randomized crossover study. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E671-E679.	3.5	8
4	The role of bile acids and their TGR5 receptor in irritable bowel syndrome and diarrhoea. Digestive and Liver Disease, 2021, 53, 1118-1119.	0.9	4
5	Role of endoscopy in chronic diarrhoea when functional bowel disease is suspected. Gut, 2020, 69, 190-191.	12.1	1
6	Bile Acid Diarrhea., 2020,, 279-286.		0
7	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Clinical Gastroenterology and Hepatology, 2020, 18, 24-41.e1.	4.4	40
8	The pathophysiology of bile acid diarrhoea: differences in the colonic microbiome, metabolome and bile acids. Scientific Reports, 2020, 10, 20436.	3.3	27
9	Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice. Frontline Gastroenterology, 2020, 11, 358-363.	1.8	21
10	Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. Alimentary Pharmacology and Therapeutics, 2020, 52, 808-820.	3.7	30
11	Tests that now deserve to be more widely adopted in IBD clinical practice. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482094408.	3.2	3
12	Making the Diagnosis of Bile Acid Diarrhea. American Journal of Gastroenterology, 2020, 115, 1974-1975.	0.4	3
13	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. Scientific Reports, 2020, 10, 3895.	3.3	27
14	A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways. Journal of Crohn's and Colitis, 2020, 14, 935-947.	1.3	81
15	Canadian Association of Gastroenterology Clinical Practice Guideline on the Management of Bile Acid Diarrhea. Journal of the Canadian Association of Gastroenterology, 2020, 3, e10-e27.	0.3	16
16	Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. PLoS ONE, 2019, 14, e0211348.	2.5	33
17	Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis. Hepatology, 2019, 70, 276-293.	7.3	46
18	What Can We Learn From Mouse Models About Bile Acid–Mediated Changes After Bariatric Surgery?. Gastroenterology, 2019, 157, 4-8.	1.3	7

#	Article	IF	Citations
19	PWE-037â€Diagnosis and management of bile acid diarrhoea: UK consensus survey of expert opinion and practice. , 2019, , .		O
20	Chronic diarrhea, bile acids, and Clostridia. Journal of Clinical Investigation, 2019, 130, 77-79.	8.2	5
21	Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition. Gut, 2018, 67, 1380-1399.	12.1	197
22	Diet1, bile acid diarrhea, and FGF15/19: mouse model and human genetic variants. Journal of Lipid Research, 2018, 59, 429-438.	4.2	27
23	Letter: longâ€ŧerm treatment of severe bile acid diarrhoeaâ€"obeticholic acid can normalise Se <scp>HCAT</scp> retention. Alimentary Pharmacology and Therapeutics, 2018, 48, 1032-1034.	3.7	3
24	Guts and Gall: Bile Acids in Regulation of Intestinal Epithelial Function in Health and Disease. Physiological Reviews, 2018, 98, 1983-2023.	28.8	184
25	Editorial: developing a stimulation test to identify <scp>FGF</scp> 19 deficiency in bile acid diarrhoea. Alimentary Pharmacology and Therapeutics, 2017, 46, 69-70.	3.7	1
26	How bad is bile acid diarrhoea: an online survey of patient-reported symptoms and outcomes. BMJ Open Gastroenterology, 2017, 4, e000116.	2.7	52
27	A positive SeHCAT test results in fewer subsequent investigations in patients with chronic diarrhoea. Frontline Gastroenterology, 2017, 8, 279-283.	1.8	27
28	Editorial: diagnosing bile acid diarrhoea with blood tests. Alimentary Pharmacology and Therapeutics, 2017, 46, 699-700.	3.7	0
29	A Twist in the Tale of a Pig Model of Short-Bowel Syndrome. Cellular and Molecular Gastroenterology and Hepatology, 2017, 4, 201-202.	4.5	1
30	Novel associations of bile acid diarrhoea with fatty liver disease and gallstones: a cohort retrospective analysis. BMJ Open Gastroenterology, 2017, 4, e000178.	2.7	15
31	Letter: hydroxypropyl cellulose as therapy for chronic diarrhoea in patients with bile acid malabsorption – possible mechanisms. Alimentary Pharmacology and Therapeutics, 2016, 44, 306-307.	3.7	6
32	The Farnesoid X Receptor: Good for BAD. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 725-732.	4.5	51
33	Characterizing Factors Associated With Differences in FGF19 Blood Levels and Synthesis in Patients With Primary Bile Acid Diarrhea. American Journal of Gastroenterology, 2016, 111, 423-432.	0.4	49
34	Editorial: colesevelam effects on faecal bile acids in <scp>IBS</scp> with diarrhoea. Alimentary Pharmacology and Therapeutics, 2015, 41, 696-697.	3.7	1
35	Diarrhea in Crohn's Disease: Investigating the Role of the Ileal Hormone Fibroblast Growth Factor 19. Journal of Crohn's and Colitis, 2015, 9, 125-131.	1.3	26
36	Physiology of malabsorption. Surgery, 2015, 33, 193-199.	0.3	2

#	Article	IF	CITATIONS
37	The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Alimentary Pharmacology and Therapeutics, 2015, 41, 54-64.	3.7	138
38	A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism. Annals of Translational Medicine, 2015, 3, S7.	1.7	8
39	The role of bile acids in functional GI disorders. Neurogastroenterology and Motility, 2014, 26, 1057-1069.	3.0	55
40	The role of near-patient coeliac serology testing in the follow-up of patients with coeliac disease. Frontline Gastroenterology, 2014, 5, 20-25.	1.8	5
41	Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 426-434.	17.8	90
42	Recycling rate of bile acids in the enterohepatic recirculation as a major determinant of whole body 75SeHCAT retention. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1618-1621.	6.4	14
43	Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Alimentary Pharmacology and Therapeutics, 2013, 38, 967-976.	3.7	97
44	Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective. Expert Review of Gastroenterology and Hepatology, 2013, 7, 49-56.	3.0	23
45	Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. American Journal of Physiology - Renal Physiology, 2013, 304, G940-G948.	3.4	90
46	The Role of Bile After Roux-en-Y Gastric Bypass in Promoting Weight Loss and Improving Glycaemic Control. Endocrinology, 2012, 153, 3613-3619.	2.8	343
47	Fibroblast Growth Factor 19 and 7α-Hydroxy-4-Cholesten-3-one in the Diagnosis of Patients With Possible Bile Acid Diarrhea. Clinical and Translational Gastroenterology, 2012, 3, e18.	2.5	58
48	Physiology of malabsorption. Surgery, 2012, 30, 268-274.	0.3	5
49	Differences in Inflammatory Bowel Disease Phenotype between South Asians and Northern Europeans Living in North West London, UK. American Journal of Gastroenterology, 2011, 106, 1281-1289.	0.4	51
50	Adequacy of flexible sigmoidoscopy with biopsy for diarrhea in patients under age 50 without features of proximal disease. Gastrointestinal Endoscopy, 2011, 73, 757-764.	1.0	13
51	* A study of the prevalence of genetic polymorphisms in bile acid diarrhoea patients. Gut, 2011, 60, A89-A89.	12.1	1
52	The role of near patient coeliac serology testing in the follow-up of patients with coeliac disease. Gut, 2011, 60, A17-A17.	12.1	1
53	* Evaluation of fibroblast growth factor 19 in the diagnosis of bile acid diarrhoea. Gut, 2011, 60, A88-A88.	12.1	0
54	New Insights into Bile Acid Malabsorption. Current Gastroenterology Reports, 2011, 13, 418-425.	2.5	43

#	Article	IF	Citations
55	Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therapeutic Advances in Gastroenterology, 2011, 4, 49-62.	3.2	68
56	New 2010 British Society of Gastroenterology colitis surveillance guidelines: costs and surveillance intervals. Gut, 2011, 60, 282-283.	12.1	11
57	PP-020â€A prospective study of fibroblast growth factor 19 in patients with chronic diarrhoea and possible bile acid malabsorption. Gut, 2010, 59, A48.1-A48.	12.1	1
58	Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Review of Gastroenterology and Hepatology, 2010, 4, 561-567.	3.0	43
59	Applicability of the reported prevalence of bile salt malabsorption in irritable bowel: authors' reply. Alimentary Pharmacology and Therapeutics, 2010, 31, 162-164.	3.7	1
60	Managing bile acid diarrhoea. Therapeutic Advances in Gastroenterology, 2010, 3, 349-357.	3.2	127
61	Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut, 2010, 59, 767-774.	12.1	184
62	Human duodenum responses to vitamin D metabolites of TRPV6 and other genes involved in calcium absorption. American Journal of Physiology - Renal Physiology, 2009, 297, G1193-G1197.	3.4	75
63	Recent advances in the understanding of bile acid malabsorption. British Medical Bulletin, 2009, 92, 79-93.	6.9	90
64	Experience of maintenance infliximab therapy for refractory ulcerative colitis from six centres in England. Alimentary Pharmacology and Therapeutics, 2009, 29, 308-314.	3.7	39
65	Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Alimentary Pharmacology and Therapeutics, 2009, 30, 423-435.	3.7	71
66	Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoeaâ€predominant irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2009, 30, 707-717.	3.7	361
67	Taurine uptake across the human intestinal brushâ€border membrane is via two transporters: H ⁺ â€coupled PAT1 (SLC36A1) and Na ⁺ ―and Cl ^{â°} â€dependent TauT (SLC6A6). Journal of Physiology, 2009, 587, 731-744.	2.9	106
68	A New Mechanism for Bile Acid Diarrhea: Defective Feedback Inhibition of Bile Acid Biosynthesis. Clinical Gastroenterology and Hepatology, 2009, 7, 1189-1194.	4.4	280
69	Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-ÂB signalling. Gut, 2009, 58, 1078-1083.	12.1	170
70	Short bowel syndrome: the role of GLP-2 on improving outcome. Current Opinion in Clinical Nutrition and Metabolic Care, 2009, 12, 526-532.	2.5	38
71	Newly identified genetic risk variants for celiac disease related to the immune response. Nature Genetics, 2008, 40, 395-402.	21.4	599
72	Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut, 2008, 57, 923-929.	12.1	426

#	Article	IF	CITATIONS
73	Coeliac disease and the risk of infections. Gut, 2008, 57, 1034-1035.	12.1	16
74	Exploring possible mechanisms for primary bile acid malabsorption: evidence for different regulation of ileal bile acid transporter transcripts in chronic diarrhoea. European Journal of Gastroenterology and Hepatology, 2008, 20, 413-422.	1.6	39
75	Analysis of the absolute risks in coeliac disease indicates the importance of the prevention of osteoporosis * Author's reply. Gut, 2007, 56, 310-311.	12.1	8
76	The effects of Vitamin D metabolites on expression of genes for calcium transporters in human duodenum. Journal of Steroid Biochemistry and Molecular Biology, 2007, 103, 509-512.	2.5	23
77	A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nature Genetics, 2007, 39, 827-829.	21.4	592
78	Review article: glucagonâ€like peptide 2 – current applications and future directions. Alimentary Pharmacology and Therapeutics, 2007, 25, 365-372.	3.7	53
79	Coeliac disease often goes undiagnosed. Practitioner, 2007, 251, 43, 45, 47 passim.	0.3	0
80	Calcium Channel TRPV6 Expression in Human Duodenum: Different Relationships to the Vitamin D System and Aging in Men and Women. Journal of Bone and Mineral Research, 2006, 21, 1770-1777.	2.8	53
81	Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut, 2006, 55, 969-972.	12.1	58
82	Recent findings in the cell and molecular biology of the small intestine. Current Opinion in Gastroenterology, 2005, 21, 135-140.	2.3	21
83	A common CTLA4 haplotype associated with coeliac disease. European Journal of Human Genetics, 2005, 13, 440-444.	2.8	76
84	Intestinal Growth in Parenterallyâ€Fed Rats Induced by the Combined Effects of Glucagonâ€like Peptide 2 and Epidermal Growth Factor. Journal of Parenteral and Enteral Nutrition, 2005, 29, 248-254.	2.6	27
85	Calcium and vitamin D in preventing fractures: Dietary intake of calcium needs to be considered. BMJ: British Medical Journal, 2005, 331, 108.2.	2.3	1
86	Increased Expression of Specific Intestinal Amino Acid and Peptide Transporter mRNA in Rats Fed by TPN Is Reversed by GLP-2. Journal of Nutrition, 2004, 134, 2957-2964.	2.9	47
87	Duodenal expression of the epithelial calcium transporter gene TRPV6: is there evidence for Vitamin D-dependence in humans?. Journal of Steroid Biochemistry and Molecular Biology, 2004, 89-90, 317-319.	2.5	14
88	Cell and molecular biology of the small intestine: new insights into differentiation, growth and repair. Current Opinion in Gastroenterology, 2004, 20, 70-76.	2.3	24
89	Human ileal bile acid-binding protein promoter and the effects of CDX2. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2003, 1630, 138-143.	2.4	9
90	Detecting the risks of osteoporotic fractures in coeliac disease. Gut, 2003, 52, 1229-a-1230.	12.1	5

#	Article	IF	Citations
91	Molecular and cellular biology of small intestinal differentiation, gene expression and hormonal responses. Current Opinion in Gastroenterology, 2003, 19, 106-112.	2.3	O
92	The role of the intestine in bone homeostasis. European Journal of Gastroenterology and Hepatology, 2003, 15, 845-849.	1.6	21
93	New advances in the molecular and cellular biology of the small intestine. Current Opinion in Gastroenterology, 2002, 18, 161-167.	2.3	17
94	Variation in the <i>CTLA4/CD28</i> gene region confers an increased risk of coeliac disease. Annals of Human Genetics, 2002, 66, 125-137.	0.8	37
95	Variation in the CTLA4/CD28 gene region confers an increased risk of coeliac disease. Annals of Human Genetics, 2002, 66, 125-37.	0.8	11
96	Epithelial calcium transporter expression in human duodenum. American Journal of Physiology - Renal Physiology, 2001, 280, G285-G290.	3.4	81
97	Molecular and cellular biology of small-bowel mucosa. Current Opinion in Gastroenterology, 2001, 17, 104-109.	2.3	3
98	The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis. British Journal of Cancer, 2001, 84, 218-225.	6.4	34
99	Characterisation of a novel murine intestinal serine protease, DISP. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2000, 1490, 131-136.	2.4	9
100	Glucagon-like peptide-2 increases sucrase-isomaltase but not caudal-related homeobox protein-2 gene expression. American Journal of Physiology - Renal Physiology, 2000, 278, G425-G428.	3.4	28
101	Bile acids are physiological ligands for a nuclear receptor. Gut, 2000, 46, 308-309.	12.1	18
102	Effects of homeobox transcription factors CDX2 and PDX1 on the calbindin-D9K promoter. Gastroenterology, 2000, 118, A287.	1.3	0
103	Effect of glucagon-like peptide 2 on functional and transcription factor gene expression in the small intestine. Gastroenterology, 2000, 118, A559.	1.3	0
104	Glucagon-like peptide 2 and epidermal growth factor, but not glutamine, have additive effects on intestinal growth. Gastroenterology, 2000, 118, Al104.	1.3	0
105	Identification and expression of the human intestinal epithelial apical membrane calcium transporter. Gastroenterology, 2000, 118, A70.	1.3	0
106	Changes in expression of intestinal peptide and amino acid transporters in rats fed by total parenteral nutrition. Gastroenterology, 2000, 118, A72-A73.	1.3	0
107	Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease. Gut, 1999, 44, 168-173.	12.1	43
108	Expression of genes involved in calcium absorption in human duodenum. European Journal of Clinical Investigation, 1999, 29, 214-219.	3.4	37

#	Article	IF	CITATIONS
109	Factors involved in the duodenal expression of the human calbindin-D9k gene. Biochemical Journal, 1999, 341, 491-500.	3.7	49
110	Factors involved in the duodenal expression of the human calbindin-D9k gene. Biochemical Journal, 1999, 341, 491.	3.7	23
111	Superior mesenteric vein stenosis complicating Crohn's disease. Gut, 1999, 45, 459-462.	12.1	9
112	Inhibition of Luciferase Expression from a Commercial Reporter Vector by 1,25-Dihydroxycholecalciferol. Analytical Biochemistry, 1998, 263, 113-115.	2.4	6
113	Regional expression of intestinal genes for nutrient absorption Gut, 1997, 40, 5-8.	12.1	15
114	Differences in expression of homeobox transcription factors in proximal and distal human small intestine. Gastroenterology, 1997, 113, 472-477.	1.3	56
115	Anti-gliadin Antibodies in Patients with Celiac Disease Cross-react with Enterocytes and Human Calreticulin. Clinical Immunology and Immunopathology, 1997, 85, 289-296.	2.0	39
116	Increased small intestinal apoptosis in coeliac disease Gut, 1996, 39, 811-817.	12.1	145
117	Detection of low bone mineral density by dual energy x ray absorptiometry in unsuspected suboptimally treated coeliac disease Gut, 1995, 37, 220-224.	12.1	77
118	Chronic intrahepatic cholestasis in sickle cell disease requiring exchange transfusion Gut, 1995, 37, 144-147.	12.1	42
119	Bone mineral density in coeliac disease Gut, 1994, 35, 150-151.	12.1	53
120	A 3-month survey of enteral tube feeding and parenteral feeding: a baseline for improvement. Journal of Human Nutrition and Dietetics, 1994, 7, 61-68.	2.5	3
121	Plasma-membrane calcium-pump isoforms in human and rat liver. Biochemical Journal, 1994, 303, 275-279.	3.7	35
122	Calretinin and calbindin-D28k immunoreactivity in the human gastrointestinal tract. Gastroenterology, 1993, 104, 1381-1389.	1.3	43
123	Addisonian crisis presenting with a normal short tetracosactrin stimulation test Postgraduate Medical Journal, 1992, 68, 465-466.	1.8	8
124	Combination therapy with oral ursodeoxycholic and chenodeoxycholic acids: pretreatment computed tomography of the gall bladder improves gall stone dissolution efficacy Gut, 1992, 33, 375-380.	12.1	27
125	Plasma membrane calcium pump expression in human placenta and small intestine. Biochemical and Biophysical Research Communications, 1992, 183, 499-505.	2.1	30
126	Molecular cloning and chromosomal assignment of human calbindin-D9K. Biochemical and Biophysical Research Communications, 1992, 185, 663-669.	2.1	41

#	Article	IF	CITATIONS
127	Lichen planus associated with chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution. Digestive Diseases and Sciences, 1992, 37, 628-630.	2.3	11
128	Stimulation of intestinal basolateral membrane calcium-pump activity by recombinant synthetic calbindin-D9k and specific mutants. Biochemical and Biophysical Research Communications, 1990, 170, 603-608.	2.1	22
129	[28] Calcium transport by intestinal epithelial cell basolateral membrane. Methods in Enzymology, 1990, 192, 448-459.	1.0	0
130	The Activity of the Basolateral Membrane Calcium-Pumping ATPase and Intestinal Calcium Transport. , 1990, , 95-101.		1
131	Identification and isolation of the phosphorylated intermediate of the calcium pump in rat intestinal basolateral membranes. Biochemical Journal, 1988, 256, 593-598.	3.7	9
132	EFFECTS OF VITAMIN D-DEFICIENCY ON DIFFERENT ACTIVITIES OF THE Ca2+-PUMP IN RAT INTESTINAL BASOLATERAL MEMBRANES, 1988, , 567-568.		0
133	Intestinal basolateral membrane Ca-ATPase activity with properties distinct from those of the Ca-pump. Biochemical and Biophysical Research Communications, 1986, 141, 979-985.	2.1	16
134	Intestinal Cell Membranes. International Review of Cytology, 1986, 101, 1-57.	6.2	35
135	Preparation of subcellular membranes from rat intestinal scrapings or isolated cells. Gastroenterology, 1986, 91, 34-40.	1.3	18
136	Decrease by cycloheximide of calcium binding and nonesterified fatty acids in rat-intestinal Golgi-enriched membrane fractions. Biochimica Et Biophysica Acta - Biomembranes, 1985, 813, 19-24.	2.6	2
137	Effect of alcohol withdrawal on blood pressure, plasma renin activity, aldosterone, cortisol and dopamine β-hydroxylase. Clinical Science, 1984, 66, 659-663.	4.3	78
138	Characterization of the vitamin D-dependent Ca2+-binding sites in rat intestinal Golgi-enriched membrane fractions. Biochemical Journal, 1984, 218, 347-354.	3.7	12
139	Relationship of non-esterified fatty acids to vitamin D-dependent Ca2+ binding by rat intestinal Golgi-enriched membrane fractions. Biochemical Journal, 1984, 218, 355-360.	3.7	12